Eli Lilly and Company

elsewhere's corpus does not cover Eli Lilly and Company directly — the retrieved material consists entirely of partner-published references to the company in deal contexts, with no dedicated profile or background article about the firm itself. What the sources do show is a pharmaceutical giant active in two directions: deepening its GLP-1 franchise through an early, cut-price licensing deal with Roche's Chugai unit (a $50 million upfront for what became a foundational weight-loss asset, per a 2024 FreeS Fund report) , and aggressively partnering with Chinese biotech and AI players — including a $345 million collaboration with XtalPi, a strategic deal with Ze'an Biopharmaceutical's myeloid engager platform, and an equity investment in AI model company ChAI with access to 150 years of Lilly data . Related coverage mentions the company only in passing across unrelated topics .